The company is investing in its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
Lonza announced on Oct. 22, 2020 that it is investing $93 million into its Capsules and Health Ingredients Division to expand its capsule production capacity by 30 billion capsules annually.
According to a company press release, the investment will be made over the course of two years at Lonza’s manufacturing sites in Bornem, Belgium; Colmar, France; Greenwood, SC; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.
"We continue to see strong demand for our products across all markets, as consumers and patients alike take a more active interest in their health,” said Claude Dartiguelongue, president, Capsules and Health Ingredients, Lonza, in the press release. “Therefore, we felt it is critical that we make this commitment to expand the manufacturing capacity of our network, not only addressing supply needs in the near term but also supply availability over the long term."
"Dosage form technologies have evolved rapidly over the past ten years,” added Stef Vanquickenborne, head of Capsules and Health Ingredients Research and Development, Lonza, in the press release. “As the leader in the industry, we are committed to innovation and helping our customers successfully deliver next-generation drugs and nutritional supplements."
Source: Lonza
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.